| Item Type | Name |
|
Concept
|
Acetates
|
|
Concept
|
Actins
|
|
Concept
|
Allylamine
|
|
Concept
|
Alanine Transaminase
|
|
Concept
|
Albumins
|
|
Concept
|
Antibodies, Bacterial
|
|
Concept
|
Antibodies, Viral
|
|
Concept
|
Alkaline Phosphatase
|
|
Concept
|
Apolipoproteins B
|
|
Concept
|
Apolipoproteins
|
|
Concept
|
Benzaldehydes
|
|
Concept
|
Acetylcholine
|
|
Concept
|
Acetylcholinesterase
|
|
Concept
|
Actinin
|
|
Concept
|
Acetaminophen
|
|
Concept
|
Cyclic AMP
|
|
Concept
|
Acetamides
|
|
Concept
|
Acute-Phase Proteins
|
|
Concept
|
Amino Acids
|
|
Concept
|
Transaminases
|
|
Concept
|
Bile Acids and Salts
|
|
Concept
|
Adenosine Triphosphate
|
|
Concept
|
Adrenergic beta-Antagonists
|
|
Concept
|
Adrenocorticotropic Hormone
|
|
Concept
|
Mineralocorticoid Receptor Antagonists
|
|
Concept
|
Actomyosin
|
|
Concept
|
Blood Proteins
|
|
Concept
|
Antigens
|
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Apolipoproteins E
|
|
Concept
|
Analgesics
|
|
Concept
|
Androsterone
|
|
Concept
|
Angiotensin-Converting Enzyme Inhibitors
|
|
Concept
|
Anticoagulants
|
|
Concept
|
Anti-Inflammatory Agents, Non-Steroidal
|
|
Concept
|
Antithrombins
|
|
Concept
|
Antiviral Agents
|
|
Concept
|
Carboxylic Acids
|
|
Concept
|
Cholecystokinin
|
|
Concept
|
Sterol O-Acyltransferase
|
|
Concept
|
Antihypertensive Agents
|
|
Concept
|
Antioxidants
|
|
Concept
|
Apolipoproteins C
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Anti-Inflammatory Agents
|
|
Concept
|
Base Sequence
|
|
Concept
|
Benzamides
|
|
Concept
|
Benzimidazoles
|
|
Concept
|
Bezafibrate
|
|
Concept
|
Cathartics
|
|
Concept
|
Aspartate Aminotransferases
|
|
Concept
|
Aspirin
|
|
Concept
|
Diuretics
|
|
Concept
|
Chlorpromazine
|
|
Concept
|
Calcium, Dietary
|
|
Concept
|
Autoantibodies
|
|
Concept
|
Bacterial Vaccines
|
|
Concept
|
Blood Glucose
|
|
Concept
|
Drug Tolerance
|
|
Concept
|
Nonprescription Drugs
|
|
Concept
|
Betaine
|
|
Concept
|
Benztropine
|
|
Concept
|
Blood Coagulation Factors
|
|
Concept
|
Calcifediol
|
|
Concept
|
Carbon Monoxide
|
|
Concept
|
Carbon Disulfide
|
|
Concept
|
Chylomicrons
|
|
Concept
|
Clozapine
|
|
Concept
|
Cholesterol, Dietary
|
|
Concept
|
Choline O-Acetyltransferase
|
|
Concept
|
Flavonoids
|
|
Concept
|
Colestipol
|
|
Concept
|
Cholesterol Esters
|
|
Concept
|
gamma-Aminobutyric Acid
|
|
Concept
|
gamma-Glutamyltransferase
|
|
Concept
|
Cisplatin
|
|
Concept
|
C-Peptide
|
|
Concept
|
C-Reactive Protein
|
|
Concept
|
Carotenoids
|
|
Concept
|
Glycerides
|
|
Concept
|
Creatine Kinase
|
|
Concept
|
Creatinine
|
|
Concept
|
Corticotropin-Releasing Hormone
|
|
Concept
|
Cytochrome b Group
|
|
Concept
|
Cholesterol
|
|
Concept
|
Coenzymes
|
|
Concept
|
Collagen
|
|
Concept
|
Contrast Media
|
|
Concept
|
Hormones
|
|
Concept
|
Consumer Product Safety
|
|
Concept
|
Immunoglobulin M
|
|
Concept
|
Dietary Carbohydrates
|
|
Concept
|
DNA-Binding Proteins
|
|
Concept
|
DNA, Mitochondrial
|
|
Concept
|
Cytochrome c Group
|
|
Concept
|
Dexamethasone
|
|
Concept
|
Docosahexaenoic Acids
|
|
Concept
|
Drug Synergism
|
|
Concept
|
Electrolytes
|
|
Concept
|
Immunosuppressive Agents
|
|
Concept
|
Insulin
|
|
Concept
|
Interleukins
|
|
Concept
|
Iron
|
|
Concept
|
Cytochrome P-450 Enzyme System
|
|
Concept
|
Drug Evaluation
|
|
Concept
|
Drug Therapy
|
|
Concept
|
Cyclophosphamide
|
|
Concept
|
Dehydroepiandrosterone
|
|
Concept
|
Galantamine
|
|
Concept
|
Glycoproteins
|
|
Concept
|
Chorionic Gonadotropin
|
|
Concept
|
Gout Suppressants
|
|
Concept
|
Haloperidol
|
|
Concept
|
Hepatitis B Antibodies
|
|
Concept
|
Lactose
|
|
Concept
|
Phosphatidylcholine-Sterol O-Acyltransferase
|
|
Concept
|
Enzyme Inhibitors
|
|
Concept
|
Estradiol
|
|
Concept
|
Lipoprotein Lipase
|
|
Concept
|
Immunoglobulin A
|
|
Concept
|
Dietary Proteins
|
|
Concept
|
Diglycerides
|
|
Concept
|
Cholagogues and Choleretics
|
|
Concept
|
Clonidine
|
|
Concept
|
Fatty Acids, Monounsaturated
|
|
Concept
|
Etoposide
|
|
Concept
|
Electron Transport Complex IV
|
|
Concept
|
Drug Interactions
|
|
Concept
|
Drug Compounding
|
|
Concept
|
Drug Resistance
|
|
Concept
|
Drug Evaluation, Preclinical
|
|
Concept
|
Drug Therapy, Combination
|
|
Concept
|
Food
|
|
Concept
|
Fatty Acids, Nonesterified
|
|
Concept
|
Fibrinogen
|
|
Concept
|
Indoles
|
|
Concept
|
Indomethacin
|
|
Concept
|
Microtubule-Associated Proteins
|
|
Concept
|
Minerals
|
|
Concept
|
Fluorocarbons
|
|
Concept
|
Fructose
|
|
Concept
|
Fatty Acids
|
|
Concept
|
Fatty Acids, Unsaturated
|
|
Concept
|
Fibronectins
|
|
Concept
|
Isoxazoles
|
|
Concept
|
Dibenzothiazepines
|
|
Concept
|
Dicarboxylic Acids
|
|
Concept
|
Diclofenac
|
|
Concept
|
Dietary Fats, Unsaturated
|
|
Concept
|
Coloring Agents
|
|
Concept
|
Dyneins
|
|
Concept
|
DNA, Viral
|
|
Concept
|
Dopamine
|
|
Concept
|
Dose-Response Relationship, Drug
|
|
Concept
|
Drug Combinations
|
|
Concept
|
Drug Labeling
|
|
Concept
|
Dyskinesia, Drug-Induced
|
|
Concept
|
Hypoglycemic Agents
|
|
Concept
|
Lipoproteins
|
|
Concept
|
Heptanoic Acids
|
|
Concept
|
Estrogens, Conjugated (USP)
|
|
Concept
|
Hydrocortisone
|
|
Concept
|
Hydroxyindoleacetic Acid
|
|
Concept
|
Hydroxymethylglutaryl CoA Reductases
|
|
Concept
|
Hypnotics and Sedatives
|
|
Concept
|
Fish Oils
|
|
Concept
|
Fluorobenzenes
|
|
Concept
|
Isoenzymes
|
|
Concept
|
Lactones
|
|
Concept
|
Gum Arabic
|
|
Concept
|
Lipoproteins, LDL
|
|
Concept
|
Margarine
|
|
Concept
|
Ketones
|
|
Concept
|
Membrane Glycoproteins
|
|
Concept
|
Homovanillic Acid
|
|
Concept
|
Membrane Proteins
|
|
Concept
|
Immunoglobulin E
|
|
Concept
|
Microfilament Proteins
|
|
Concept
|
Phentermine
|
|
Concept
|
Phospholipids
|
|
Concept
|
Vitamin K 1
|
|
Concept
|
Lipids
|
|
Concept
|
Midazolam
|
|
Concept
|
Nerve Tissue Proteins
|
|
Concept
|
Esters
|
|
Concept
|
Estrogens
|
|
Concept
|
Prothrombin
|
|
Concept
|
Indoleacetic Acids
|
|
Concept
|
Glycogen
|
|
Concept
|
Oximes
|
|
Concept
|
Mevalonic Acid
|
|
Concept
|
Mitoxantrone
|
|
Concept
|
Peptide Fragments
|
|
Concept
|
RNA, Transfer, Leu
|
|
Concept
|
Naphthalenes
|
|
Concept
|
Phenols
|
|
Concept
|
Phosphorus
|
|
Concept
|
Oxazepam
|
|
Concept
|
Ligands
|
|
Concept
|
Lipopolysaccharides
|
|
Concept
|
Cholesterol, HDL
|
|
Concept
|
Safety
|
|
Concept
|
Organophosphorus Compounds
|
|
Concept
|
Oxazepines
|
|
Concept
|
Parasympathomimetics
|
|
Concept
|
Perphenazine
|
|
Concept
|
Methylcellulose
|
|
Concept
|
Plant Proteins
|
|
Concept
|
Phosphoprotein Phosphatases
|
|
Concept
|
Narcotic Antagonists
|
|
Concept
|
Norethindrone
|
|
Concept
|
Oxygen
|
|
Concept
|
Sulfhydryl Compounds
|
|
Concept
|
Sulfones
|
|
Concept
|
Phenobarbital
|
|
Concept
|
Drug Prescriptions
|
|
Concept
|
Fenofibrate
|
|
Concept
|
Prednisone
|
|
Concept
|
Progestins
|
|
Concept
|
Physostigmine
|
|
Concept
|
Piperazines
|
|
Concept
|
Plasmids
|
|
Concept
|
Protein Precursors
|
|
Concept
|
Protein-Tyrosine Kinases
|
|
Concept
|
Prostaglandins
|
|
Concept
|
Proteoglycans
|
|
Concept
|
Proteins
|
|
Concept
|
Pyridines
|
|
Concept
|
Homocysteine
|
|
Concept
|
Mixed Function Oxygenases
|
|
Concept
|
Glucans
|
|
Concept
|
Glutamine
|
|
Concept
|
Glycine
|
|
Concept
|
Immunoglobulin G
|
|
Concept
|
Receptors, Cell Surface
|
|
Concept
|
Receptors, Serotonin
|
|
Concept
|
Reference Standards
|
|
Concept
|
Prostaglandin-Endoperoxide Synthases
|
|
Concept
|
Vasoactive Intestinal Peptide
|
|
Concept
|
Venoms
|
|
Concept
|
Protein Kinases
|
|
Concept
|
Psyllium
|
|
Concept
|
Purines
|
|
Concept
|
Quinolines
|
|
Concept
|
Receptors, Immunologic
|
|
Concept
|
Receptors, LDL
|
|
Concept
|
Viral Hepatitis Vaccines
|
|
Concept
|
Somatostatin
|
|
Concept
|
RNA, Viral
|
|
Concept
|
Cholesterol, VLDL
|
|
Concept
|
Receptors, Cholinergic
|
|
Concept
|
Receptors, Histamine
|
|
Concept
|
Receptors, Prostaglandin
|
|
Concept
|
Cadherins
|
|
Concept
|
Interleukin-6
|
|
Concept
|
Sitosterols
|
|
Concept
|
Serotonin
|
|
Concept
|
RNA
|
|
Concept
|
Steroid 11-beta-Hydroxylase
|
|
Concept
|
Sulfonylurea Compounds
|
|
Concept
|
Heparin
|
|
Concept
|
Hepatitis Antibodies
|
|
Concept
|
Hepatitis B Surface Antigens
|
|
Concept
|
Sulfonic Acids
|
|
Concept
|
Ibuprofen
|
|
Concept
|
Lipoproteins, VLDL
|
|
Concept
|
Sterols
|
|
Concept
|
Tetrazoles
|
|
Concept
|
Indans
|
|
Concept
|
United States Food and Drug Administration
|
|
Concept
|
Triglycerides
|
|
Concept
|
Biomarkers, Tumor
|
|
Concept
|
Tumor Necrosis Factor-alpha
|
|
Concept
|
Ubiquinone
|
|
Concept
|
Lipoprotein(a)
|
|
Concept
|
Plasminogen Activator Inhibitor 1
|
|
Concept
|
Warfarin
|
|
Concept
|
Vasodilator Agents
|
|
Concept
|
Drug Design
|
|
Concept
|
Inulin
|
|
Concept
|
Lipase
|
|
Concept
|
Cholesterol, LDL
|
|
Concept
|
Lovastatin
|
|
Concept
|
Thyrotropin
|
|
Concept
|
Thyroxine
|
|
Concept
|
Anti-Anxiety Agents
|
|
Concept
|
Nicotinic Agonists
|
|
Concept
|
Galanin
|
|
Concept
|
Tyrosine
|
|
Concept
|
Vitamin E
|
|
Concept
|
Water
|
|
Concept
|
Raloxifene Hydrochloride
|
|
Concept
|
Hepatitis A Vaccines
|
|
Concept
|
Vitamins
|
|
Concept
|
Myosin Type II
|
|
Concept
|
2-Acetylaminofluorene
|
|
Concept
|
Yohimbine
|
|
Concept
|
Vaccines, Inactivated
|
|
Concept
|
Vinculin
|
|
Concept
|
Synaptophysin
|
|
Concept
|
Fatty Acids, Omega-3
|
|
Concept
|
25-Hydroxyvitamin D 2
|
|
Concept
|
Apolipoprotein A-I
|
|
Concept
|
Gemfibrozil
|
|
Concept
|
Paclitaxel
|
|
Concept
|
Adverse Drug Reaction Reporting Systems
|
|
Concept
|
Cytochalasin D
|
|
Concept
|
Drug Approval
|
|
Concept
|
Drug Delivery Systems
|
|
Concept
|
Neuropeptides
|
|
Concept
|
Dextran Sulfate
|
|
Concept
|
Prostate-Specific Antigen
|
|
Concept
|
Minocycline
|
|
Concept
|
Peroxidase
|
|
Concept
|
Naproxen
|
|
Concept
|
Integrin alpha5beta1
|
|
Concept
|
Amyloid beta-Protein Precursor
|
|
Concept
|
Receptors, sigma
|
|
Concept
|
Cyclooxygenase Inhibitors
|
|
Concept
|
Receptors, Cytoplasmic and Nuclear
|
|
Concept
|
Receptors, AMPA
|
|
Concept
|
Inflammation Mediators
|
|
Concept
|
Antigens, CD34
|
|
Concept
|
beta Carotene
|
|
Concept
|
Fat Substitutes
|
|
Concept
|
GABA Agonists
|
|
Concept
|
Qa-SNARE Proteins
|
|
Concept
|
Synaptosomal-Associated Protein 25
|
|
Concept
|
Simvastatin
|
|
Concept
|
src-Family Kinases
|
|
Concept
|
Dietary Sucrose
|
|
Concept
|
Cyclooxygenase 2 Inhibitors
|
|
Concept
|
Caspase 3
|
|
Concept
|
Myristic Acid
|
|
Concept
|
Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent
|
|
Concept
|
Drosophila Proteins
|
|
Concept
|
Oxazines
|
|
Concept
|
Protein Tyrosine Phosphatases
|
|
Concept
|
Reactive Oxygen Species
|
|
Concept
|
Orphan Nuclear Receptors
|
|
Concept
|
Oxazolidinones
|
|
Concept
|
Hepatitis A Antibodies
|
|
Concept
|
Green Fluorescent Proteins
|
|
Concept
|
1-Alkyl-2-acetylglycerophosphocholine Esterase
|
|
Concept
|
Creatine Kinase, MM Form
|
|
Concept
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors
|
|
Concept
|
Interleukin-1beta
|
|
Concept
|
rhoA GTP-Binding Protein
|
|
Concept
|
Nonmuscle Myosin Type IIA
|
|
Concept
|
Receptors, Dopamine D3
|
|
Concept
|
Phosphopyruvate Hydratase
|
|
Concept
|
Plant Oils
|
|
Concept
|
Piperidines
|
|
Concept
|
Prolactin
|
|
Concept
|
Promoter Regions, Genetic
|
|
Concept
|
Pyrazoles
|
|
Concept
|
Apolipoprotein B-100
|
|
Concept
|
Pyrimidines
|
|
Concept
|
Quinazolines
|
|
Concept
|
Receptors, Dopamine
|
|
Concept
|
Receptors, Muscarinic
|
|
Concept
|
Recombinant Proteins
|
|
Concept
|
Pyrroles
|
|
Concept
|
Rhodamines
|
|
Concept
|
RNA, Ribosomal, 16S
|
|
Concept
|
Serine
|
|
Concept
|
Serum Albumin
|
|
Concept
|
RNA, Messenger
|
|
Concept
|
Spironolactone
|
|
Concept
|
Farnesyl-Diphosphate Farnesyltransferase
|
|
Concept
|
Dihydrotestosterone
|
|
Concept
|
Proprotein Convertases
|
|
Concept
|
Sulfonamides
|
|
Concept
|
Thiazolidinediones
|
|
Concept
|
Mannose-Binding Lectin
|
|
Concept
|
Testosterone
|
|
Concept
|
Shc Signaling Adaptor Proteins
|
|
Concept
|
Serotonin 5-HT2 Receptor Antagonists
|
|
Concept
|
Polyphenols
|
|
Concept
|
Antipsychotic Agents
|
|
Concept
|
Sterol Regulatory Element Binding Protein 1
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Concept
|
beta-Glucans
|
|
Concept
|
Growth Hormone
|
|
Concept
|
Apolipoprotein E4
|
|
Concept
|
Steroids
|
|
Concept
|
Vanadates
|
|
Concept
|
Vitamin D
|
|
Concept
|
Adaptor Proteins, Signal Transducing
|
|
Concept
|
Sucrose
|
|
Concept
|
Tablets
|
|
Concept
|
Zinc
|
|
Concept
|
Serine Proteinase Inhibitors
|
|
Concept
|
Cyclooxygenase 2
|
|
Concept
|
Hepatocyte Nuclear Factor 4
|
|
Concept
|
Cyclosporine
|
|
Concept
|
Drug Monitoring
|
|
Concept
|
beta-Alanine
|
|
Concept
|
Medroxyprogesterone Acetate
|
|
Concept
|
Haemophilus Vaccines
|
|
Concept
|
Granulocyte Colony-Stimulating Factor
|
|
Concept
|
Amyloid beta-Peptides
|
|
Concept
|
ATP-Binding Cassette Transporters
|
|
Concept
|
Chemokine CCL2
|
|
Concept
|
CD36 Antigens
|
|
Concept
|
Serotonin Receptor Agonists
|
|
Concept
|
NADPH Oxidases
|
|
Concept
|
Cholesterol Ester Transfer Proteins
|
|
Concept
|
Presenilin-1
|
|
Concept
|
Receptors, CCR2
|
|
Concept
|
Phospholipases A2
|
|
Concept
|
Dipeptidyl-Peptidase IV Inhibitors
|
|
Concept
|
Dexmedetomidine
|
|
Concept
|
Immobilized Proteins
|
|
Concept
|
Mucin-1
|
|
Concept
|
Nootropic Agents
|
|
Concept
|
Alendronate
|
|
Concept
|
Anti-Obesity Agents
|
|
Concept
|
Chemical and Drug Induced Liver Injury
|
|
Concept
|
Histone Deacetylase Inhibitors
|
|
Concept
|
Gadolinium DTPA
|
|
Concept
|
Fatty Acids, Omega-6
|
|
Concept
|
Fatty Acid Desaturases
|
|
Concept
|
Extracellular Signal-Regulated MAP Kinases
|
|
Concept
|
Adrenergic beta-2 Receptor Agonists
|
|
Concept
|
Glucagon-Like Peptide 1
|
|
Concept
|
AMP-Activated Protein Kinases
|
|
Concept
|
Lectins, C-Type
|
|
Concept
|
Intracellular Signaling Peptides and Proteins
|
|
Concept
|
Cytochrome P-450 CYP3A
|
|
Concept
|
Quinazolinones
|
|
Concept
|
Apolipoprotein C-III
|
|
Concept
|
rho-Associated Kinases
|
|
Concept
|
Incretins
|
|
Concept
|
Drug Discovery
|
|
Concept
|
Fibric Acids
|
|
Concept
|
Amides
|
|
Concept
|
Anti-Bacterial Agents
|
|
Concept
|
Anticholesteremic Agents
|
|
Concept
|
Hypolipidemic Agents
|
|
Concept
|
ATP Citrate (pro-S)-Lyase
|
|
Concept
|
Azetidines
|
|
Concept
|
Calcium
|
|
Concept
|
Calcium Channel Blockers
|
|
Concept
|
Capsules
|
|
Concept
|
Carrier Proteins
|
|
Concept
|
Cholinesterase Inhibitors
|
|
Concept
|
Clofibric Acid
|
|
Concept
|
Colchicine
|
|
Concept
|
Corn Oil
|
|
Concept
|
Delayed-Action Preparations
|
|
Concept
|
Dietary Fats
|
|
Concept
|
Diethylnitrosamine
|
|
Concept
|
Dosage Forms
|
|
Concept
|
Drug Administration Schedule
|
|
Concept
|
Drug Resistance, Microbial
|
|
Concept
|
Epidermal Growth Factor
|
|
Concept
|
Epinephrine
|
|
Concept
|
Fat Emulsions, Intravenous
|
|
Concept
|
Fluorescent Dyes
|
|
Concept
|
Folic Acid
|
|
Concept
|
Glucose
|
|
Concept
|
Hematinics
|
|
Concept
|
Ketone Bodies
|
|
Concept
|
Lipoproteins, HDL
|
|
Concept
|
Luminescent Proteins
|
|
Concept
|
Methoxyhydroxyphenylglycol
|
|
Concept
|
Niacin
|
|
Concept
|
Nicotine
|
|
Concept
|
Norepinephrine
|
|
Concept
|
Oligonucleotides
|
|
Concept
|
Pectins
|
|
Concept
|
Peptides
|
|
Concept
|
Phenformin
|
|
Concept
|
Phytosterols
|
|
Concept
|
Platelet Aggregation Inhibitors
|
|
Concept
|
Progesterone
|
|
Concept
|
Psychotropic Drugs
|
|
Concept
|
Receptors, Adrenergic
|
|
Concept
|
Recombinant Fusion Proteins
|
|
Concept
|
RNA, Ribosomal
|
|
Concept
|
Serine Endopeptidases
|
|
Concept
|
Etidronic Acid
|
|
Concept
|
Tolbutamide
|
|
Concept
|
Vaccines, Synthetic
|
|
Concept
|
Vimentin
|
|
Concept
|
Vitamin A
|
|
Concept
|
Eicosapentaenoic Acid
|
|
Concept
|
Integrins
|
|
Concept
|
Pravastatin
|
|
Concept
|
Receptors, Dopamine D2
|
|
Concept
|
DNA Primers
|
|
Concept
|
Dopamine Antagonists
|
|
Concept
|
Risperidone
|
|
Concept
|
Bridged Bicyclo Compounds, Heterocyclic
|
|
Concept
|
alpha-Tocopherol
|
|
Concept
|
Adaptor Proteins, Vesicular Transport
|
|
Concept
|
Quantum Dots
|
|
Concept
|
Peroxisome Proliferator-Activated Receptors
|
|
Concept
|
Scavenger Receptors, Class A
|
|
Concept
|
Adiponectin
|
|
Concept
|
Chylomicron Remnants
|
|
Concept
|
Apolipoprotein C-II
|
|
Concept
|
CARD Signaling Adaptor Proteins
|
|
Concept
|
Thiazolidines
|
|
Concept
|
p21-Activated Kinases
|
|
Concept
|
Patient Safety
|
|
Academic Article
|
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
|
|
Academic Article
|
Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial.
|
|
Academic Article
|
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group.
|
|
Academic Article
|
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.
|
|
Academic Article
|
Statin trials in progress: unanswered questions.
|
|
Academic Article
|
Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo-dehydroepiandrosterone in healthy male volunteers.
|
|
Academic Article
|
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia.
|
|
Academic Article
|
What kinds of data should be available to probe the effects of nutrients, food supplements or vitamins on serum lipoprotein levels and/or atherosclerosis?
|
|
Academic Article
|
A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group.
|
|
Academic Article
|
Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women.
|
|
Academic Article
|
Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study.
|
|
Academic Article
|
Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.
|
|
Academic Article
|
A multiple-dose pharmacodynamic, safety, and pharmacokinetic comparison of extended- and immediate-release formulations of lovastatin.
|
|
Academic Article
|
Introduction: utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agents.
|
|
Academic Article
|
Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia.
|
|
Academic Article
|
Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia.
|
|
Academic Article
|
Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent.
|
|
Academic Article
|
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia.
|
|
Academic Article
|
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
|
|
Academic Article
|
Cholesterol-lowering drugs bring benefits to high-risk populations even when LDL is normal.
|
|
Academic Article
|
Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia.
|
|
Academic Article
|
Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial.
|
|
Academic Article
|
Efficacy of over-the-counter nutritional supplements.
|
|
Academic Article
|
Safety and tolerability of esterified phytosterols administered in reduced-fat spread and salad dressing to healthy adult men and women.
|
|
Academic Article
|
Management of hypercholesterolaemia in postmenopausal women.
|
|
Academic Article
|
Combination therapy for dyslipidemia: safety and regulatory considerations.
|
|
Academic Article
|
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.
|
|
Academic Article
|
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
|
|
Academic Article
|
The safety and immunogenicity of a CETP vaccine in healthy adults.
|
|
Academic Article
|
Possible differences between fibrates in pharmacokinetic interactions with statins.
|
|
Academic Article
|
Combination lipid-lowering therapy in diabetes.
|
|
Academic Article
|
Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia.
|
|
Academic Article
|
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
|
|
Academic Article
|
Rosuvastatin safety: lessons from the FDA review and post-approval surveillance.
|
|
Academic Article
|
Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
|
|
Academic Article
|
Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia.
|
|
Academic Article
|
Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia.
|
|
Academic Article
|
Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin.
|
|
Academic Article
|
Ezetimibe: a novel option for lowering cholesterol.
|
|
Academic Article
|
Reducing residual risk for patients on statin therapy: the potential role of combination therapy.
|
|
Academic Article
|
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.
|
|
Academic Article
|
Striated muscle safety of ezetimibe/simvastatin (Vytorin).
|
|
Academic Article
|
Statin safety: an assessment using an administrative claims database.
|
|
Academic Article
|
Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia.
|
|
Academic Article
|
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
|
|
Academic Article
|
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
|
|
Academic Article
|
Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy.
|
|
Academic Article
|
Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
|
|
Academic Article
|
Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors.
|
|
Academic Article
|
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
|
|
Academic Article
|
Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
|
|
Academic Article
|
Combination therapy in the management of complex dyslipidemias.
|
|
Academic Article
|
Flushing ASsessment Tool (FAST): psychometric properties of a new measure assessing flushing symptoms and clinical impact of niacin therapy.
|
|
Academic Article
|
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
|
|
Academic Article
|
Statin safety: an appraisal from the adverse event reporting system.
|
|
Academic Article
|
Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
|
|
Academic Article
|
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.
|
|
Academic Article
|
Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
|
|
Academic Article
|
Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.
|
|
Academic Article
|
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
|
|
Academic Article
|
Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
|
|
Academic Article
|
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
|
|
Academic Article
|
Squalene synthase inhibition: a novel target for the management of dyslipidemia.
|
|
Academic Article
|
A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al.
|
|
Academic Article
|
Safety of aggressive lipid management.
|
|
Academic Article
|
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
|
|
Academic Article
|
Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study.
|
|
Academic Article
|
Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies.
|
|
Academic Article
|
The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review.
|
|
Academic Article
|
High-dose statin therapy: benefits and safety in aggressive lipid lowering.
|
|
Academic Article
|
Atherosclerosis surrogate imaging trials come of age: for better or for worse?
|
|
Academic Article
|
Statin and ezetimibe combination therapy in cardiovascular disease.
|
|
Academic Article
|
Safety of anacetrapib in patients with or at high risk for coronary heart disease.
|
|
Academic Article
|
Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease.
|
|
Academic Article
|
Drugs in development for management of lipoprotein disorders.
|
|
Academic Article
|
Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction.
|
|
Academic Article
|
One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
|
|
Academic Article
|
Is ezetimibe/simvastatin no better than simvastatin alone? Lessons learned and clinical implications.
|
|
Academic Article
|
Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet.
|
|
Academic Article
|
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
|
|
Academic Article
|
Pharmacokinetic interactions between statins and fibrates.
|
|
Academic Article
|
Cholesterol absorption blockade with ezetimibe.
|
|
Academic Article
|
A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia.
|
|
Academic Article
|
Peripheral artery disease, biomarkers, and darapladib.
|
|
Academic Article
|
Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
|
|
Academic Article
|
Should niacin be the preferred drug to add to a statin?
|
|
Academic Article
|
Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (= 2 mg/L). cmb@bcm.tmc.edu.
|
|
Academic Article
|
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.
|
|
Academic Article
|
Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy.
|
|
Academic Article
|
Safety considerations with fibrate therapy.
|
|
Academic Article
|
Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia.
|
|
Academic Article
|
Gemfibrozil treatment in patients with elevated lipoprotein a: a pilot study.
|
|
Academic Article
|
Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy.
|
|
Academic Article
|
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
|
|
Academic Article
|
Apolipoprotein A-I therapy promise, challenges, and disappointment.
|
|
Academic Article
|
Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study).
|
|
Academic Article
|
Bl-1020, a new ?-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
|
|
Academic Article
|
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day.
|
|
Academic Article
|
Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial.
|
|
Academic Article
|
Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia.
|
|
Academic Article
|
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group.
|
|
Academic Article
|
Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia.
|
|
Academic Article
|
Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions.
|
|
Academic Article
|
Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia.
|
|
Academic Article
|
Risk for myopathy with statin therapy in high-risk patients.
|
|
Academic Article
|
Efficacy of simvastatin and ezetimibe in treating hypercholesterolemia.
|
|
Academic Article
|
Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events.
|
|
Academic Article
|
Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS).
|
|
Academic Article
|
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups.
|
|
Academic Article
|
Torcetrapib/atorvastatin combination therapy.
|
|
Academic Article
|
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.
|
|
Academic Article
|
Rosuvastatin in elderly patients.
|
|
Academic Article
|
Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
|
|
Academic Article
|
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
|
|
Academic Article
|
A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
|
|
Academic Article
|
A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia.
|
|
Academic Article
|
Therapies targeting exogenous cholesterol uptake: new insights and controversies.
|
|
Academic Article
|
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
|
|
Academic Article
|
Fluvastatin Long-Term Extension Trial (FLUENT): summary of efficacy and safety.
|
|
Academic Article
|
Diagnostic and pharmacological approaches in Alzheimer's disease.
|
|
Academic Article
|
Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
|
|
Academic Article
|
Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.
|
|
Academic Article
|
Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
|
|
Academic Article
|
Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation.
|
|
Academic Article
|
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial.
|
|
Academic Article
|
Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.
|
|
Academic Article
|
Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
|
|
Academic Article
|
Limitations of controlled augmentation trials in schizophrenia.
|
|
Academic Article
|
Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials.
|
|
Academic Article
|
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group.
|
|
Academic Article
|
Pharmacological approaches to modifying HDL: more basic science to understand HDL metabolism is necessary. Editorial to: "NO-1886 up-regulates Niemann-Pick C1 protein (NPC1) expression through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells" by Xin Ma et al.
|
|
Academic Article
|
Controversy surrounding the safety of cerivastatin.
|
|
Academic Article
|
Influence of filgrastim (granulocyte colony-stimulating factor) on human immunodeficiency virus type 1 RNA in patients with cytomegalovirus retinitis.
|
|
Academic Article
|
Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy.
|
|
Academic Article
|
Perceived patient threat and neuroleptic dosage.
|
|
Academic Article
|
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
|
|
Academic Article
|
A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
|
|
Academic Article
|
Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors.
|
|
Academic Article
|
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
|
|
Academic Article
|
Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting.
|
|
Academic Article
|
Marine oil capsule therapy for the treatment of hyperlipidemia.
|
|
Academic Article
|
Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned.
|
|
Academic Article
|
Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
|
|
Academic Article
|
Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies.
|
|
Academic Article
|
Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.
|
|
Academic Article
|
Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia.
|
|
Academic Article
|
Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans.
|
|
Academic Article
|
Underappreciated opportunities for high-density lipoprotein particles in risk stratification and potential targets of therapy.
|
|
Academic Article
|
Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial.
|
|
Academic Article
|
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
|
|
Academic Article
|
Combination therapy with statins: who benefits?
|
|
Academic Article
|
Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials.
|
|
Academic Article
|
A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease.
|
|
Academic Article
|
Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
|
|
Academic Article
|
Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms.
|
|
Academic Article
|
Risk factors for nasopharyngeal carriage of resistant Streptococcus pneumoniae and detection of a multiply resistant clone among children living in the Yukon-Kuskokwim Delta region of Alaska.
|
|
Academic Article
|
Panel discussion: what is the future of macronutrient substitutes in North America?
|
|
Academic Article
|
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
|
|
Academic Article
|
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
|
|
Academic Article
|
Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose.
|
|
Academic Article
|
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.
|
|
Academic Article
|
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).
|
|
Academic Article
|
Recent developments in the treatment of familial hypercholesterolemia: a review of several new drug classes.
|
|
Academic Article
|
Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study.
|
|
Academic Article
|
Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.
|
|
Academic Article
|
A pilot study of clonidine plus physostigmine in Alzheimer's disease.
|
|
Academic Article
|
Overcoming toxicity and side-effects of lipid-lowering therapies.
|
|
Academic Article
|
Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).
|
|
Academic Article
|
The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients.
|
|
Academic Article
|
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.
|
|
Academic Article
|
LIMITATIONS IN THE USE OF ORAL HYPOGLYCEMIC AGENTS IN JUVENILE PATIENTS WITH DIABETES.
|
|
Academic Article
|
A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.
|
|
Academic Article
|
The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter?
|
|
Academic Article
|
The future of n-3 polyunsaturated fatty acid therapy.
|
|
Academic Article
|
Intensive statin therapy in India: Demonstrating efficacy and safety.
|
|
Academic Article
|
Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.
|
|
Academic Article
|
Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia.
|
|
Academic Article
|
Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers.
|
|
Academic Article
|
No Effect of Omega-3 Carboxylic Acids on Pharmacokinetics/Pharmacodynamics of Warfarin or on Platelet Function When Co-administered with Acetylsalicylic Acid: Results of Two Phase I Studies in Healthy Volunteers.
|
|
Academic Article
|
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.
|
|
Academic Article
|
Effects of ipsapirone in healthy subjects: a dose-response study.
|
|
Academic Article
|
Long-term safety of risperidone.
|
|
Academic Article
|
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?
|
|
Academic Article
|
Assessment of pharmacokinetic interaction between omega-3 carboxylic acids and the statins rosuvastatin and simvastatin: Results of 2 phase I studies in healthy volunteers.
|
|
Academic Article
|
Carbon disulfide poisoning: a review.
|
|
Academic Article
|
Can We Cure Atherosclerosis?
|
|
Academic Article
|
Cardiorenal Safety of OTC Analgesics.
|
|
Academic Article
|
Lower On-Treatment Low-Density Lipoprotein Cholesterol and Major Adverse Cardiovascular Events in Women and Men: Pooled Analysis of 10 ODYSSEY Phase 3 Alirocumab Trials.
|
|
Academic Article
|
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
|
|
Academic Article
|
PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety.
|
|
Academic Article
|
Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals.
|
|
Academic Article
|
Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
|
|
Academic Article
|
Inactivated hepatitis A vaccine: a safety and immunogenicity study in health professionals.
|
|
Academic Article
|
Short-term effects of coping skills training as adjunct to intensive therapy in adolescents.
|
|
Academic Article
|
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
|
|
Academic Article
|
Effect of Adjunctive Estradiol on Schizophrenia Among Women of Childbearing Age: A Randomized Clinical Trial.
|
|
Academic Article
|
Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials.
|
|
Concept
|
Ezetimibe, Simvastatin Drug Combination
|
|
Concept
|
Drug-Related Side Effects and Adverse Reactions
|
|
Concept
|
Hepcidins
|
|
Concept
|
Hypromellose Derivatives
|
|
Concept
|
Cytochrome P-450 Enzyme Inhibitors
|
|
Concept
|
Cytochrome P-450 CYP3A Inhibitors
|
|
Concept
|
ErbB Receptors
|
|
Academic Article
|
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial.
|
|
Academic Article
|
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial.
|